Literature DB >> 628054

Carcinoembryonic antigen test for recurrent colorectal carcinoma. Inadequacy for early detection.

C G Moertel, A J Schutt, V L Go.   

Abstract

Serum carcinoembryonic antigen (CEA) tests were performed on 36 patients with histologically proved locally recurrent or residual malignant disease after resection of colorectal carcinoma but with no clinical evidence of distant metastasis. Only nine patients (25%) had abnormal CEA levels of greater than 5 ng/ml despite the fact that most patients had had symptoms of recurrence for several months. Among the nine of our patients, none had CEA values greater than 5 ng/ml, and only three had levels greater than 2.5 ng/ml (3.4, 3.8, and 4.7 ng/ml). The CEA assay is not a sensitive test for early detection of recurrence of colorectal carcinoma.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 628054

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  22 in total

Review 1.  History and present status of pulmonary metastasectomy in colorectal cancer.

Authors:  Tom Treasure; Mišel Milošević; Francesca Fiorentino; Joachim Pfannschmidt
Journal:  World J Gastroenterol       Date:  2014-10-28       Impact factor: 5.742

2.  Symposium: The management of recurrent colorectal cancer.

Authors:  F F Attiyeh; H Ellis; M Killingback; G D Oates; P F Schofield; H J Staab; G Steele; P H Sugarbaker
Journal:  Int J Colorectal Dis       Date:  1986-07       Impact factor: 2.571

3.  The role of CEA, TPA and CA 19-9 in the early detection of recurrent colorectal cancer.

Authors:  P Barillari; G Ramacciato; R de Angelis; P Gozzo; P Aurello; M Indinnimeo; S Valabrega; F D'Angelo; G Fegiz
Journal:  Int J Colorectal Dis       Date:  1989-12       Impact factor: 2.571

4.  Carcinoembryonic antigen and recurrent colorectal cancer.

Authors:  J Northover
Journal:  Gut       Date:  1986-02       Impact factor: 23.059

5.  Accuracy of monitoring serum carcinoembryonic antigen levels in postoperative stage III colorectal cancer patients is limited to only the first postoperative year.

Authors:  Masayasu Hara; Mikinori Sato; Hiroki Takahashi; Satoru Takayama; Hiromitsu Takeyama
Journal:  Surg Today       Date:  2011-09-16       Impact factor: 2.549

6.  Systematic follow-up after curative surgery for colorectal cancer in Norway: a population-based audit of effectiveness, costs, and compliance.

Authors:  Hartwig Körner; Kjetil Söreide; Pål J Stokkeland; Jon Arne Söreide
Journal:  J Gastrointest Surg       Date:  2005-03       Impact factor: 3.452

7.  CEA monitoring among patients in multi-institutional adjuvant G.I. therapy protocols.

Authors:  G Steele; S Ellenberg; K Ramming; M O'Connell; C Moertel; H Lessner; H Bruckner; J Horton; P Schein; N Zamcheck; J Novak; E D Holyoke
Journal:  Ann Surg       Date:  1982-08       Impact factor: 12.969

8.  Carcinoembryonic antigen: physician attitudes, patterns of use, and impact upon patient care.

Authors:  S L Vest; J K Roche
Journal:  Dig Dis Sci       Date:  1982-04       Impact factor: 3.199

9.  Use of CEA as an indicator of early recurrence and as a guide to a selected second-look procedure in patients with colorectal cancer.

Authors:  J H Wanebo; M Stearns; M K Schwartz
Journal:  Ann Surg       Date:  1978-10       Impact factor: 12.969

Review 10.  Carcinoembryonic antigen in patients with breast or colon cancer.

Authors:  Y N Lee
Journal:  West J Med       Date:  1978-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.